Introduction of an order set after hip fracture improves osteoporosis medication initiation and persistence: a population-based before-after analysis.

IF 4.2 2区 医学 Q1 ENDOCRINOLOGY & METABOLISM
Osteoporosis International Pub Date : 2024-10-01 Epub Date: 2024-06-05 DOI:10.1007/s00198-024-07131-3
Gabriel Larose, Saeed Al-Azazi, Lisa M Lix, Eric Bohm, William D Leslie
{"title":"Introduction of an order set after hip fracture improves osteoporosis medication initiation and persistence: a population-based before-after analysis.","authors":"Gabriel Larose, Saeed Al-Azazi, Lisa M Lix, Eric Bohm, William D Leslie","doi":"10.1007/s00198-024-07131-3","DOIUrl":null,"url":null,"abstract":"<p><p>We found that a standardized order set after hip fracture increased initiation of anti-osteoporosis medication and increased persistence at 1 year, but did not reduce secondary fractures.</p><p><strong>Background: </strong>A treatment gap exists after osteoporosis-related fractures. Introducing standardized care can improve treatment. We evaluated the impact of a hip fracture order set (OS) on anti-osteoporosis medication (AOM) initiation, persistence, and secondary fracture prevention.</p><p><strong>Methods: </strong>In 2015, one hospital in Manitoba, Canada, introduced a hip fracture OS including recommendations for the initiation of AOM (OS group). A control group was identified from the other hospitals in the same region. A retrospective cohort study was conducted using linked administrative health data. All individuals 50 + years with surgical treatment for low-energy hip fracture between 2010 and 2019 were included and followed for AOM initiation, medication persistence at 1 year, and secondary fractures. Between-group differences for each year were assessed using chi-square tests. Logistic regression models tested the impact of socio-demographic and clinical factors on initiation, persistence of AOM. Cox regression tested the risk of secondary fracture.</p><p><strong>Results: </strong>No baseline differences between OS group (813 patients) and control group (2150 patients) were observed in demographics, socioeconomic factors, or comorbidities. An increase in post-fracture AOM initiation was seen with OS introduction (OS group year before 16.7% versus year after 48.6%, p < 0.001). No change was seen in the control group. Persistence on AOM also increased (OS group year before 17.7% versus year after 28.4%, p < 0.001). No difference in secondary fractures was observed (OS group 19.8% versus control group 18.8%, p = 0.38).</p><p><strong>Conclusion: </strong>Introduction of a hip fracture OS significantly increased AOM initiation and persistence at 1-year post-fracture. There was no significant difference in secondary fractures.</p>","PeriodicalId":19638,"journal":{"name":"Osteoporosis International","volume":null,"pages":null},"PeriodicalIF":4.2000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Osteoporosis International","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00198-024-07131-3","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/6/5 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

We found that a standardized order set after hip fracture increased initiation of anti-osteoporosis medication and increased persistence at 1 year, but did not reduce secondary fractures.

Background: A treatment gap exists after osteoporosis-related fractures. Introducing standardized care can improve treatment. We evaluated the impact of a hip fracture order set (OS) on anti-osteoporosis medication (AOM) initiation, persistence, and secondary fracture prevention.

Methods: In 2015, one hospital in Manitoba, Canada, introduced a hip fracture OS including recommendations for the initiation of AOM (OS group). A control group was identified from the other hospitals in the same region. A retrospective cohort study was conducted using linked administrative health data. All individuals 50 + years with surgical treatment for low-energy hip fracture between 2010 and 2019 were included and followed for AOM initiation, medication persistence at 1 year, and secondary fractures. Between-group differences for each year were assessed using chi-square tests. Logistic regression models tested the impact of socio-demographic and clinical factors on initiation, persistence of AOM. Cox regression tested the risk of secondary fracture.

Results: No baseline differences between OS group (813 patients) and control group (2150 patients) were observed in demographics, socioeconomic factors, or comorbidities. An increase in post-fracture AOM initiation was seen with OS introduction (OS group year before 16.7% versus year after 48.6%, p < 0.001). No change was seen in the control group. Persistence on AOM also increased (OS group year before 17.7% versus year after 28.4%, p < 0.001). No difference in secondary fractures was observed (OS group 19.8% versus control group 18.8%, p = 0.38).

Conclusion: Introduction of a hip fracture OS significantly increased AOM initiation and persistence at 1-year post-fracture. There was no significant difference in secondary fractures.

Abstract Image

髋部骨折后引入订单组可改善骨质疏松症用药的初始性和持续性:一项基于人群的用药前后分析。
我们发现,髋部骨折后的标准化医嘱增加了抗骨质疏松症药物的使用率,并提高了1年后的持续用药率,但并未减少继发性骨折的发生:背景:骨质疏松症相关骨折后存在治疗缺口。背景:骨质疏松症相关骨折后存在治疗差距,引入标准化护理可改善治疗。我们评估了髋部骨折医嘱集(OS)对抗骨质疏松药物(AOM)的启动、持续性和继发性骨折预防的影响:2015年,加拿大马尼托巴省的一家医院推出了髋部骨折诊疗单,其中包括关于开始使用AOM的建议(诊疗单组)。从同一地区的其他医院中确定了一个对照组。这项回顾性队列研究使用了相关的行政健康数据。研究纳入了2010年至2019年期间接受过低能量髋部骨折手术治疗的所有50岁以上的患者,并对他们的AOM启动情况、1年后的用药持续情况和继发性骨折情况进行了随访。每年的组间差异采用卡方检验进行评估。逻辑回归模型检验了社会人口和临床因素对开始和持续服用AOM的影响。Cox回归测试了继发性骨折的风险:OS 组(813 名患者)与对照组(2150 名患者)在人口统计学、社会经济因素或合并症方面没有基线差异。随着 OS 的引入,骨折后开始 AOM 的比例有所上升(OS 组前一年为 16.7%,后一年为 48.6%,P 结论:OS 的引入显著增加了髋部骨折后 AOM 的发生率:引入髋部骨折OS后,AOM的发生率和骨折后1年的持续率明显增加。在继发性骨折方面没有明显差异。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Osteoporosis International
Osteoporosis International 医学-内分泌学与代谢
CiteScore
8.10
自引率
10.00%
发文量
224
审稿时长
3 months
期刊介绍: An international multi-disciplinary journal which is a joint initiative between the International Osteoporosis Foundation and the National Osteoporosis Foundation of the USA, Osteoporosis International provides a forum for the communication and exchange of current ideas concerning the diagnosis, prevention, treatment and management of osteoporosis and other metabolic bone diseases. It publishes: original papers - reporting progress and results in all areas of osteoporosis and its related fields; review articles - reflecting the present state of knowledge in special areas of summarizing limited themes in which discussion has led to clearly defined conclusions; educational articles - giving information on the progress of a topic of particular interest; case reports - of uncommon or interesting presentations of the condition. While focusing on clinical research, the Journal will also accept submissions on more basic aspects of research, where they are considered by the editors to be relevant to the human disease spectrum.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信